Related Experiment Video
Updated: Apr 21, 2026

Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
SARS-CoV-2 main protease inhibition by natural compounds
Gisele Strieder Philippsen1, Lucas Yudai Nozaki2, Michael Jackson Vieira da Silva3
1Universidade Federal do Paraná, Brazil.
None:
The pandemic caused by the SARS-CoV-2 virus established the urgency in the development of vaccines and specific antivirals. Currently, vaccines and one specific medicine (Paxlovid) are available. Despite this, the research for therapeutic resources is still active to expand the possibilities for COVID-19 treatment. In this work, the libraries of natural compounds from Sigma-Aldrich and Molport were computationally screened, aiming to identify potential inhibitors against the SARS-CoV-2 main protease. The compounds SID336241534, SID264573190, and SID336181660 were identified as potential ligands and had their inhibitory activity against SARS-CoV-2 main protease confirmed by the in vitro proteolytic activity assays, suggesting their use as leads for the optimization of more efficient inhibitors. The in vivo and clinical tests are still needed to explore the applicability of the prospected compounds for the COVID-19 treatment.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Enzyme Inhibition
Inhibitors of Bacterial Protein Synthesis
Inhibition of Cdk Activity
Inhibition of CDK Activity

